Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 7Burkitt Lymphoma 6Smoldering Multiple Myeloma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Biphenotypic, Acute 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Meningioma 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Down Syndrome 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Dexamethasone 4iberdomide 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Lenalidomide 2Curcumin 2Calcium Dobesilate 2selinexor 1isatuximab 1daratumumab 1Resistance Training 1Propranolol 1Probiotics 1Docosahexaenoic Acids 1Dietary Fiber 1Diet, Plant-Based 1Diet, Mediterranean 1Blood Specimen Collection 1Behavior Therapy 1Adrenergic beta-Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Smoldering Multiple Myeloma × auricularum × Clear all
NCT04776395 2026-06-01

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Emory University

Phase 2 Recruiting
68 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡